JP2024517829A5 - - Google Patents
Info
- Publication number
- JP2024517829A5 JP2024517829A5 JP2023568006A JP2023568006A JP2024517829A5 JP 2024517829 A5 JP2024517829 A5 JP 2024517829A5 JP 2023568006 A JP2023568006 A JP 2023568006A JP 2023568006 A JP2023568006 A JP 2023568006A JP 2024517829 A5 JP2024517829 A5 JP 2024517829A5
- Authority
- JP
- Japan
- Prior art keywords
- retention system
- gastric retention
- weight
- release rate
- rate regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184760P | 2021-05-05 | 2021-05-05 | |
| US63/184,760 | 2021-05-05 | ||
| PCT/US2022/072115 WO2022236289A1 (en) | 2021-05-05 | 2022-05-04 | Gastric residence systems comprising methadone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517829A JP2024517829A (ja) | 2024-04-23 |
| JP2024517829A5 true JP2024517829A5 (enExample) | 2025-05-09 |
Family
ID=83932453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568006A Pending JP2024517829A (ja) | 2021-05-05 | 2022-05-04 | メタドンを含む胃内滞留システム |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240335400A1 (enExample) |
| EP (1) | EP4333824A4 (enExample) |
| JP (1) | JP2024517829A (enExample) |
| CN (1) | CN117615755A (enExample) |
| AU (1) | AU2022270208A1 (enExample) |
| CA (1) | CA3216743A1 (enExample) |
| IL (1) | IL308211A (enExample) |
| WO (1) | WO2022236289A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| BR112021018496A2 (pt) | 2019-03-20 | 2021-11-30 | Lyndra Therapeutics Inc | Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica |
| AU2020242062B2 (en) | 2019-03-20 | 2025-12-11 | Nortiva Bio, Inc. | Coatings for gastric residence dosage forms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011276170B2 (en) * | 2010-07-06 | 2016-03-10 | Grunenthal Gmbh | Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid |
| AU2013369379B2 (en) * | 2012-12-27 | 2018-03-15 | Hennig Arzneimittel Gmbh & Co. Kg | Monolithic dosage form for the modified release of an active ingredient combination |
| US11576859B2 (en) * | 2015-10-23 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| WO2017100367A1 (en) * | 2015-12-08 | 2017-06-15 | Lyndra, Inc. | Geometric configurations for gastric residence systems |
| SG11201901294QA (en) * | 2016-09-13 | 2019-03-28 | Alar Pharmaceuticals Inc | Sustained-release buprenorphine formulations background of invention |
| JP2019532947A (ja) * | 2016-09-30 | 2019-11-14 | リンドラ，インコーポレイティド | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| CA3066658A1 (en) * | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
-
2022
- 2022-05-04 JP JP2023568006A patent/JP2024517829A/ja active Pending
- 2022-05-04 EP EP22799801.0A patent/EP4333824A4/en active Pending
- 2022-05-04 CN CN202280046388.1A patent/CN117615755A/zh active Pending
- 2022-05-04 CA CA3216743A patent/CA3216743A1/en active Pending
- 2022-05-04 AU AU2022270208A patent/AU2022270208A1/en not_active Abandoned
- 2022-05-04 IL IL308211A patent/IL308211A/en unknown
- 2022-05-04 WO PCT/US2022/072115 patent/WO2022236289A1/en not_active Ceased
- 2022-05-04 US US18/289,326 patent/US20240335400A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517829A5 (enExample) | ||
| JP2022058688A5 (enExample) | ||
| CA2628200A1 (en) | Solid pharmaceutical compositions containing pregabalin | |
| JP2017527285A5 (enExample) | ||
| KR102221846B1 (ko) | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 | |
| HUP0301887A2 (hu) | Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz | |
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| MXPA04009977A (es) | Formulaciones de tramadol de liberacion sostenida con eficacia clinica durante 24 horas. | |
| CA2635313A1 (en) | Triple combination release multi-layered tablet | |
| WO2009113703A3 (en) | Orally-disintegrating solid preparation | |
| JP2004501190A5 (enExample) | ||
| JP2005528430A5 (enExample) | ||
| JP2024518156A5 (enExample) | ||
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| KR20180011624A (ko) | 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형 | |
| US20150231084A1 (en) | Osmotic floating tablets | |
| BR112022011295A2 (pt) | Forma de dosagem para uso no tratamento ou na prevenção de uma doença | |
| BR9612213A (pt) | Composição farmaceutica oralmente liberada modificada contendo 5-asa e método para o tratamento de doenças do instetino. | |
| WO2010071320A3 (ko) | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 | |
| NO20070522L (no) | Oral vedvarende frigivelsesformulering av tedisamil med gastriske bibeholdelsesegenskaper | |
| JP2019504024A5 (enExample) | ||
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| JP2008503540A (ja) | 経口抗菌医薬組成物 | |
| EP2010158A1 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
| RU2007142557A (ru) | Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения |